TheraRadar
← Back
Data updated: May 24, 2026

AM THERAP

Generics

AM THERAP is a generic drug manufacturer focused on Cardiovascular, Respiratory, Infectious Disease.

1987
Since
19
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

Upcoming FDA Decisions

Full Calendar →
Jun 10, 2026 — Oclaiz (CAM2029, octreotide subcutaneous depot)
15d

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 55%
1 drugs
Respiratory 18%
0 drugs Phase 2: 1
Infectious Disease 9%
0 drugs Phase 1: 1
Metabolic 9%
0 drugs Phase 1: 1
Oncology 9%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
1
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling